224 related articles for article (PubMed ID: 175026)
1. Establishment of EBNA-expressing cell lines by infection of Epstein-Barr virus (EBV)-genome-negative human lymphoma cells with different EBV strains.
Fresen KO; Hausen H
Int J Cancer; 1976 Feb; 17(2):161-6. PubMed ID: 175026
[TBL] [Abstract][Full Text] [Related]
2. Transient induction of a nuclear antigen unrelated to Epstein-Barr nuclear antigen in cells of two human B-lymphoma lines converted by Epstein-Barr virus.
Fresen KO; zur Hausen H
Proc Natl Acad Sci U S A; 1977 Jan; 74(1):363-6. PubMed ID: 189313
[TBL] [Abstract][Full Text] [Related]
3. Primary EBV infection of human umbilical cord lymphocytes and EBV genome-negative lymphoblastoid cell lines (BJAB and Ramos).
Takimoto T; Sato H; Ogura H
Auris Nasus Larynx; 1986; 13(3):199-205. PubMed ID: 3036055
[TBL] [Abstract][Full Text] [Related]
4. Antigen-inducing ability of herpesvirus papio in human and baboon lymphoma lines, compared to Epstein-Barr virus.
Klein G; Falk L; Falk K
Intervirology; 1978; 10(3):153-64. PubMed ID: 210135
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity of Epstein-Barr virus originating from P3HR-1 cells. I. Studies on EBNA induction.
Fresen KO; Merkt B; Bornkamm GW; Hausen H
Int J Cancer; 1977 Mar; 19(3):317-23. PubMed ID: 191406
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of Epstein-Barr virus. IV. Induction of a specific antigen by EBV from two transformed marmoset cell lines in Ramos cells.
Fresen KO; Cho MS; zur Hausen H
Int J Cancer; 1978 Aug; 22(2):160-5. PubMed ID: 81181
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of Epstein-Barr virus derived from P3HR-1 cells.
zur Hausen H; Fresen KO
IARC Sci Publ (1971); 1978; (20):391-6. PubMed ID: 215522
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines.
Finke J; Rowe M; Kallin B; Ernberg I; Rosén A; Dillner J; Klein G
J Virol; 1987 Dec; 61(12):3870-8. PubMed ID: 2824821
[TBL] [Abstract][Full Text] [Related]
9. Production of rabbit antibodies against the viral capsid antigen (VCA) of the Epstein-Barr virus (EBV).
Vestergaard BF; Hesse J; Norrild B; Klein G
Int J Cancer; 1978 Mar; 21(3):323-8. PubMed ID: 75856
[TBL] [Abstract][Full Text] [Related]
10. Molecular size variation of EBNA is determined by the EB viral genome.
Gergely L; Sternås L; Dillner J; Klein G
Intervirology; 1984; 22(2):85-96. PubMed ID: 6090339
[TBL] [Abstract][Full Text] [Related]
11. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection.
Klein G; Giovanella B; Westman A; Stehlin JS; Mumford D
Intervirology; 1975; 5(6):319-34. PubMed ID: 181343
[TBL] [Abstract][Full Text] [Related]
12. Host cell-dependent regulation of growth transformation-associated Epstein-Barr virus antigens in somatic cell hybrids.
Contreras-Salazar B; Klein G; Masucci MG
J Virol; 1989 Jun; 63(6):2768-72. PubMed ID: 2542588
[TBL] [Abstract][Full Text] [Related]
13. Somatic cell hybrids between human lymphoma lines. II. Spontaneous and induced patterns of the Epstein-Barr virus (EBV) cycle.
Klein G; Clements G; Zeuthen J; Westman A
Int J Cancer; 1976 Jun; 17(6):715-24. PubMed ID: 59708
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a second Epstein-Barr virus-determined nuclear antigen associated with the BamHI WYH region of EBV DNA.
Dillner J; Kallin B; Ehlin-Henriksson B; Timar L; Klein G
Int J Cancer; 1985 Mar; 35(3):359-66. PubMed ID: 2982749
[TBL] [Abstract][Full Text] [Related]
15. Somatic cell hybrids between human lymphoma cell lines. V. IdUrd inducibility and P3HR-1 superinfectability of Daudi/HeLa (DAD) and Daudi/P3HR-1 (DIP-1) cell lines.
Moar MH; Ber R; Klein G; Westman A; Eriksson I
Int J Cancer; 1978 Dec; 22(6):669-74. PubMed ID: 82545
[TBL] [Abstract][Full Text] [Related]
16. Differential inhibition of Epstein-Barr virus induction by the amino acid analogue, L-canavanine.
Yamamoto N; Mueller-Lantzsch N; zur Hausen H
Int J Cancer; 1980 Apr; 25(4):439-43. PubMed ID: 6246007
[TBL] [Abstract][Full Text] [Related]
17. Qualitative and quantitative analyses of Epstein-Barr virus early antigen diffuse component by western blotting enzyme-linked immunosorbent assay with a monoclonal antibody.
Lin JC; Choi EI; Pagano JS
J Virol; 1985 Mar; 53(3):793-9. PubMed ID: 2983091
[TBL] [Abstract][Full Text] [Related]
18. Infection of EBV-genome-negative and -positive human lymphoblastoid cell lines with biologically different preparations of EBV.
Klein G; Sugden B; Leibold W; Menezes J
Intervirology; 1974; 3(4):232-44. PubMed ID: 4376804
[TBL] [Abstract][Full Text] [Related]
19. Inducibility of the Epstein-Barr virus (EBV) cycle and surface marker properties of EBV-negative lymphoma lines and their in vitro EBV-converted sublines.
Klein G; Zeuthen J; Terasaki P; Billing R; Honig R; Jondal M; Westman A; Clements G
Int J Cancer; 1976 Nov; 18(5):639-52. PubMed ID: 62724
[TBL] [Abstract][Full Text] [Related]
20. Effects of DNA synthesis inhibitors on early antigen expression following primary infection or superinfection by Epstein-Barr virus.
Lidin BI; Lamon EW
Arch Virol; 1983; 77(1):13-25. PubMed ID: 6312934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
